Management of Clostridioides difficile Infection in Hospitalized Ulcerative Colitis Patients with Positive PCR and Negative Toxin
1. Screening and Diagnostic Principles
- The British Society of Gastroenterology (BSG) recommends that all hospitalized patients with acute severe ulcerative colitis be screened for C. difficile, and that treatment be started when infection is identified, irrespective of whether the diagnosis is made by PCR or toxin assay. 1
- PCR testing is more sensitive than toxin assays, which have a false‑negative rate of approximately 15–30 %. 2
2. Antimicrobial Therapy for C. difficile
- Initiate oral vancomycin 500 mg four times daily for a 10‑day course in patients with PCR‑positive C. difficile infection, even when the toxin assay is negative. 3
3. Concurrent Ulcerative Colitis Management
- Continue intravenous corticosteroids (e.g., hydrocortisone 100 mg every 6 h or methylprednisolone 60–80 mg daily) for the ulcerative colitis flare while treating the infection. [3][1]
- Do not withhold corticosteroids when C. difficile infection is present; simultaneous therapy is required. 3
- Provide thromboprophylaxis with low‑molecular‑weight heparin in all admitted patients. 1
- Discontinue any non‑essential antibiotics that may precipitate C. difficile overgrowth, when clinically feasible. (guideline recommendation)
4. Endoscopic Evaluation
- Perform flexible sigmoidoscopy within 48 hours of admission to assess ulcerative colitis severity, obtain biopsies for cytomegalovirus testing, and look for deep ulceration; a full colonoscopy is avoided in fulminant disease. [3][1]
5. Early Assessment of Steroid Response (Day‑3)
- Objective criteria predicting ≥85 % likelihood of steroid failure: >8 bowel movements per day or 3–8 movements per day together with a C‑reactive protein > 45 mg/L. 3
- If these criteria are met, initiate rescue therapy with infliximab or cyclosporine while maintaining the vancomycin regimen. [3][1]
6. Monitoring Parameters
- Daily senior gastroenterology review with documentation of stool frequency, full blood count, CRP, and electrolytes. [3][1]
- For C. difficile response, expect clinical improvement (reduced stool frequency or softer consistency) within 3–5 days of starting vancomycin. (clinical guideline)
7. Escalation and Surgical Consultation
- Indications for surgical referral include:
8. Therapeutic Pitfalls to Avoid
- Do not delay antimicrobial therapy while awaiting repeat testing; PCR positivity in the context of severe symptoms mandates immediate treatment. (guideline recommendation)
- Do not use metronidazole as first‑line therapy for severe C. difficile infection; oral vancomycin is preferred. (guideline recommendation)
All statements are derived from guideline‑level evidence (British Society of Gastroenterology) and peer‑reviewed literature, with the strength of recommendation implicit in the guideline citations.
Inpatient Treatment for Ulcerative Colitis Flare-Ups
Diagnostic Criteria and Immediate Management
- The European Crohn’s and Colitis Organisation recommends that all patients with acute severe ulcerative colitis (ASUC) should be admitted immediately and started on intravenous corticosteroids without delay, along with comprehensive baseline investigations including mandatory testing for Clostridioides difficile 4, 5
- Patients meeting modified Truelove and Witts criteria should be admitted, which includes >6 bloody stools per day PLUS at least one of: temperature >37.8°C, heart rate >90 bpm, hemoglobin <105 g/L, or C-reactive protein >30 mg/L 4, 5, 6
First-Line Treatment and Monitoring
- The European Society of Gastrointestinal Endoscopy recommends starting IV corticosteroids immediately without waiting for stool culture results, with a preferred regimen of methylprednisolone 60-80 mg IV daily or hydrocortisone 100 mg IV four times daily 4, 5, 6
- Essential concurrent measures include withholding 5-ASA medications, accurate stool chart recording, and daily senior gastroenterology review with FBC, U&E, CRP monitoring 4, 6, 7
Rescue Therapy and Management of Complications
- The American Gastroenterological Association recommends that infliximab and cyclosporine are equally effective rescue agents for steroid-refractory disease, though infliximab is often preferred for ease of use and familiarity 6
- If C. difficile is diagnosed, treat immediately with oral vancomycin 500 mg four times daily for 10 days AND continue corticosteroids for the UC flare 6, 8
Transition to Oral Therapy and Discharge
- The European Crohn’s and Colitis Organisation recommends switching to oral prednisolone 40 mg daily when <4 bowel movements per day for 2 consecutive days and no rectal bleeding 4, 6
- Discharge criteria include at least 24 hours stable on oral therapy without worsening, completion of loading doses if on infliximab, and arrangement for maintenance therapy 4, 6, 9